PureTech Health (PRTC) EBITDA Margin (2024 - 2025)

PureTech Health (PRTC) reported EBITDA Margin of 2419.29% for Q2 2025, up 85.75% on a QoQ basis from 16973.26% in Q4 2024.

PureTech Health (PRTC) has 2 years of EBITDA Margin data on file, last reported at 2419.29% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 38.10%
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 18.35%
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 17.24%
10 PureTech Health 86.36 Mn -190.94 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -2,419.29%
Dec 31, 2024 -16,973.26%